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ABSTRACT
OBJECTIVE
To examine the dose-response relation between 
reduction in dietary sodium and blood pressure 
change and to explore the impact of intervention 
duration.
DESIGN
Systematic review and meta-analysis following 
PRISMA guidelines.
DATA SOURCES
Ovid MEDLINE(R), EMBASE, and Cochrane Central 
Register of Controlled Trials (Wiley) and reference lists 
of relevant articles up to 21 January 2019.
INCLUSION CRITERIA
Randomised trials comparing different levels of 
sodium intake undertaken among adult populations 
with estimates of intake made using 24 hour urinary 
sodium excretion.
DATA EXTRACTION AND ANALYSIS
Two of three reviewers screened the records 
independently for eligibility. One reviewer extracted 
all data and the other two reviewed the data for 
accuracy. Reviewers performed random effects meta-
analyses, subgroup analyses, and meta-regression.
RESULTS
133 studies with 12 197 participants were included. 
The mean reductions (reduced sodium v usual 
sodium) of 24 hour urinary sodium, systolic blood 
pressure (SBP), and diastolic blood pressure (DBP) 
were 130 mmol (95% confidence interval 115 to 145, 
P<0.001), 4.26 mm Hg (3.62 to 4.89, P<0.001), and 
2.07 mm Hg (1.67 to 2.48, P<0.001), respectively. 
Each 50 mmol reduction in 24 hour sodium excretion 
was associated with a 1.10 mm Hg (0.66 to 1.54; 
P<0.001) reduction in SBP and a 0.33 mm Hg (0.04 
to 0.63; P=0.03) reduction in DBP. Reductions in 
blood pressure were observed in diverse population 
subsets examined, including hypertensive and non-
hypertensive individuals. For the same reduction in 24 
hour urinary sodium there was greater SBP reduction 
in older people, non-white populations, and those 
with higher baseline SBP levels. In trials of less than 
15 days’ duration, each 50 mmol reduction in 24 hour 
urinary sodium excretion was associated with a 1.05 
mm Hg (0.40 to 1.70; P=0.002) SBP fall, less than half 
the effect observed in studies of longer duration (2.13 
mm Hg; 0.85 to 3.40; P=0.002). Otherwise, there 
was no association between trial duration and SBP 
reduction.
CONCLUSIONS
The magnitude of blood pressure lowering achieved 
with sodium reduction showed a dose-response 
relation and was greater for older populations, 
non-white populations, and those with higher blood 
pressure. Short term studies underestimate the effect 
of sodium reduction on blood pressure.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42019140812.
Introduction
High blood pressure is a leading modifiable risk factor 
for cardiovascular disease, which caused at least 17.8 
million deaths worldwide in 2017.1 A higher intake of 
dietary sodium is associated with a higher level of blood 
pressure in animals and humans.2-4 The physiological 
requirement for sodium in humans is less than 1 g 
a day,5 but currently most populations consume a 
much higher level.6 The maximum daily intake of 
dietary sodium recommended by the World Health 
Organisation (WHO) is 2 g (5 g salt) for adults,7 and 
most countries recommend reducing intake to less than 
2.4 g a day8 9 as part of a dietary approach to prevent 
high blood pressure and cardiovascular disease.
The effect of sodium reduction on blood pressure and 
the risk of cardiovascular disease has been examined 
in numerous studies. Although there is a consensus 
among health and scientific organisations to reduce 
intake of dietary sodium in the general population,8-10 
a few scientists have claimed that the benefit of 
sodium restriction for populations with normal blood 
pressure is small11 12 and could increase blood lipid 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
An extensive body of evidence has shown that a higher level of dietary sodium 
intake is associated with a higher blood pressure 
There are clear effects of sodium reduction on blood pressure in those with 
hypertension, but uncertainty persists about the comparability of effects in 
different population subsets. In addition, the impact of intervention duration is 
not fully understood
WHAT THIS STUDY ADDS
Evidence shows that sodium reduction lowers blood pressure in both 
hypertensive and non-hypertensive individuals, with greater effects in high risk 
subsets
The magnitude of blood pressure lowering achieved with sodium reduction 
showed a dose-response relation 
Very short term trials could substantially underestimate the effect of sodium 
reduction on blood pressure
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levels and the risk of mortality.12-14 Others suggest that 
a higher risk of mortality at low sodium intake levels 
is an artefact attributable to factors such as reverse 
causation and biased estimation of sodium intake.15 16
The nature of the association between change 
in sodium intake and blood pressure is key to 
understanding the potential for health interventions 
based on sodium reduction. Previous overviews 
of the data were limited because a definitive dose-
response relation could not be determined, especially 
for participants with normal blood pressure.12 17-19 
A specific issue in previous meta-analyses was the 
inclusion of studies with sodium intake estimated from 
fractional urine samples.11 12 19 Fractional urine samples 
can produce overestimates of sodium intake when true 
intake is low but underestimates when true intake is 
high.20 Studies of short duration might also confound 
estimates of the average effect of change in sodium intake 
on blood pressure because large, short term reductions 
in sodium could elicit a different type of blood pressure 
response.21 A previous analysis that included 15 studies 
with measurements made at multiple time points 
was unable to determine whether effects of sodium 
reduction on blood pressure were sustained, declined, 
or increased with greater duration of intervention.22 The 
objective of this systematic review and meta-analysis 
was to examine the dose-response relation between 
dietary sodium reduction and blood pressure change, 
and to explore the impact of intervention duration, by 
applying more restricted inclusion criteria compared 
with previous reviews. The review was conducted with 
the support of the TRUE consortium.23
Methods
Search strategy
We carried out a search following a strategy developed 
for a previous meta-analysis21 that used keyword 
searches based on “sodium chloride, dietary,” 
“sodium, dietary,” or “diet, sodium-restricted” and 
“randomized controlled trial,” “controlled clinical 
trial,” or “randomized” (supplementary file 1). The 
databases searched included Ovid MEDLINE(R), 
EMBASE, and Cochrane Central Register of Controlled 
Trials (Wiley). The search date was from the start date 
of the databases to 21 January 2019. Additionally, we 
reviewed the references of pertinent original studies 
and review articles to identify additional studies. We 
imposed no language restriction on our search.
Inclusion and exclusion criteria
Two of three reviewers (LH, KT, and SY) independently 
assessed records identified from the search for 
eligibility. We resolved any discrepancies by 
consensus. We included only trials with random 
allocation of participants to reduced dietary sodium 
intake and usual/higher dietary sodium intake (that 
is, control). Trials with concomitant interventions (eg, 
non-pharmacological interventions, antihypertensive 
or other drugs) were included only if the other 
interventions were applied equally to all randomised 
groups of interest. We included only studies with 
sodium intake estimated by 24 hour urine collection 
that also had data on systolic blood pressure or 
diastolic blood pressure measurements. Studies with 
only mean arterial blood pressure reported were not 
included unless we could retrieve relevant data from 
the authors. We excluded studies conducted in children 
(age <18 years), pregnant women, or individuals with 
confounding chronic conditions such as chronic 
kidney disease or heart failure.
Study quality
Study quality was assessed independently by two 
reviewers based on the five domains defined by the 
Cochrane Collaboration’s tool for assessing risk of bias 
version 5.0.124; namely, random sequence generation, 
allocation concealment, blinding of participants, 
personnel and outcome assessors, incomplete outcome 
data, and selective outcome reporting.
Data extraction
One author (LH) extracted all data and two authors (KT 
and SY) reviewed the data for accuracy. Data sought 
for extraction included: characteristics of the study; 
demographics of the participants (race, mean age, 
percentage of female sex, percentage hypertension); 
study design (parallel group or crossover trial); risk 
of bias; duration of the intervention (calculated as 
the period from randomisation to the last follow-up 
measurement in parallel group studies and as the 
duration of each period of intervention, excluding 
run-in and washout, in crossover studies); 24 hour 
urinary sodium and blood pressure at baseline; and 
Studies > days
Studies > days and
salt reduction ≤ mmol
Study design Systematic reviewwith meta-analysis
Excluded pregnant women and patients
with chronic kidney disease or heart failure
All studies
Studies ≤ days
Change of systolic
blood pressure¹ (% CI)Data
points
High
High
Evidence quality
(GRADE score)
High
High
58
48
135
77
9196
7410
12173
2977
© 2020 BMJ Publishing group Ltd. (mm Hg)/ mmol salt reductionhttp://bit.ly/BMJsodium
Outcomes
There is a dose-response relation between salt reduction and blood 
pressure lowering. Very short-term trials underestimate the effect 
of salt reduction on blood pressure. Population-wide salt reduction 
is recommended
Summary
Visual Abstract Salt and hypertension 
The effect of salt reduction on blood pressure
12 197 participants aged ≥ years133 trialsData sources
Comparison Intervention
Reduced
salt intake
Comparator
Usual or higher
salt intake
- -
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intervention effect on 24 hour urinary sodium and 
blood pressure.
For studies that only reported results as subgroups 
(eg, male and female subgroups), we obtained overall 
estimates as weighted averages based on the size of 
the subgroups for the primary analysis, following 
the Cochrane Handbook for Systematic Reviews of 
Interventions.24
Where available, data were extracted for subgroups 
defined by age, sex, ethnic group, and presence or 
absence of hypertension. We used casual blood pressure 
measurements rather than 24 hour ambulatory blood 
pressure if both were reported, and supine blood 
pressure was used ahead of standing blood pressure. 
In crossover studies, the last measurement of 24 hour 
urinary sodium and blood pressure at the highest 
sodium intake period was taken as the baseline.
The intervention effects on the 24 hour urinary 
sodium, systolic blood pressure, and diastolic blood 
pressure, were extracted directly from the studies, 
if reported. If not, we calculated them in crossover 
studies as the differences between the end of lowest 
sodium intake period (intervention) and the end of the 
highest sodium intake (control) period. For parallel 
studies, we calculated these as the differences between 
groups in the change from baseline to the last follow-
up measurement.
Corresponding standard errors of each outcome were 
either extracted directly or calculated from standard 
deviations, confidence intervals, or exact P values 
following the Cochrane Handbook for Systematic 
Reviews of Interventions.24 If we could not derive the 
exact variance of the paired difference, we imputed it 
by assuming a correlation coefficient of 0.5 between 
the initial and final measurement following the same 
method used in a previous meta-analysis.21 We applied 
sensitivity analyses using different levels of correlation 
coefficients from 0.1 to 0.9 with 0.1 increments to 
check sensitivity to the assumption of a 0.5 correlation.
Statistical analysis
We used random effects meta-analysis, based on the 
DerSimonian and Laird method, to generate pooled 
estimates of the intervention effect on 24 hour 
urinary sodium excretion, systolic blood pressure, 
and diastolic blood pressure. We used the I2 statistic 
to examine the heterogeneity between trial results and 
used funnel plots and Egger’s regression test to detect 
potential publication bias.
To explore the dose-response relation, we 
summarised the changes in systolic and diastolic blood 
pressure by categorising trials into five equal groups 
(quintiles) based on the change in 24 hour urinary 
sodium excretion. We plotted studies with more than 
two levels of dietary sodium intake in a connected line 
graph.
We assessed the effect of intervention duration on 
changes in blood pressure by grouping trials into five 
categories (≤7 days; >7 days to ≤14 days; >14 days to ≤30 
days; >30 days to ≤6 months; >6 months). In addition, 
for studies with multiple follow-up measurements, we 
plotted the effects on blood pressure standardised to 
50 mmol reduction of 24 hour urinary sodium against 
the duration of intervention in a connected line graph.
Age, sex, ethnic group, baseline sodium intake, 
and baseline blood pressure have been previously 
identified as potential modifiers of the effect of 
sodium reduction on blood pressure.21 We therefore 
summarised the effects on blood pressure for 
subgroups of trials (or subgroups within trials) 
defined by: mean age bands (≤35; >35 to ≤45; >45 
to ≤55; >55 to ≤65; >65 years; unknown); sex (male; 
female; mixed; unknown); ethnicity (white; black; 
Asian; mixed race; unknown); mean baseline 24 
hour sodium excretion (lowest <109 mmol; middle 
≥109 to ≤209 mmol; highest >209 mmol)25; blood 
pressure status (normotensive; hypertensive; mixed; 
unknown); and mean baseline systolic blood pressure 
groups (<120; ≥120 to <130; ≥130 to <140; ≥140 to 
<150; ≥150 to <160, ≥160 mm Hg; unknown). The 
effects were standardised to a 50 mmol difference in 
24 hour urinary sodium with variance estimated using 
the Taylor expansion.
To further explore the effects of these variables on 
blood pressure response to sodium reduction, we 
conducted unadjusted meta-regression for change 
in 24 hour urinary sodium, duration of intervention, 
mean age, percentage of white ethnicity, percentage 
of female sex, mean baseline blood pressure, and 
mean baseline 24 hour sodium excretion. We also did 
multivariable meta-regression including all covariates 
except for baseline 24 hour sodium excretion, which 
showed strong collinearity with the change in 24 hour 
urinary sodium (r=0.83). The following steps were 
undertaken to minimise missing data in the meta-
regression analyses: if the studies did not report the 
participants’ race, this was imputed based on the study 
country (66 data points); if the percentage of female 
participants was not reported, the mean percentage of 
female of all other studies was used (8 data points); 
if only the age range was reported, the mean age was 
estimated as the mean of the minimum and maximum 
(12 data points); if neither mean age nor age range 
were reported, the mean age of all other studies was 
used (3 data points); and if baseline blood pressure 
was not reported, the mean value of all other studies 
was used (2 data points).
Short term studies are usually done using very 
restricted diets and could result in sudden large 
reductions in sodium intake that do not reflect medium 
or long term effects of sodium reduction on blood 
pressure.21 26 Accordingly, we conducted stratified 
analyses for studies with intervention duration of 14 
days or less versus more than 14 days. For the same 
reason, we also did an analysis restricted to trials longer 
than 14 days with a 100 mmol or smaller reduction in 
24 hour urinary sodium. All analyses were done using 
Stata (version 15.1, StataCorp, TX).
Patient and public involvement
Patients and the public were not involved in the design 
and conduct of this review.
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Results
The search identified 17 477 records. After screening 
titles and abstracts, we selected 462 publications 
for full text review, of which 329 were excluded for 
the reasons summarised in figure 1. One hundred 
and thirty three studies27-159 met our inclusion 
criteria, with 136 data points extracted for primary 
analyses involving 12 197 participants (fig 1) and 
169 data points for various subgroup analyses. The 
characteristics of the included studies are presented 
in supplementary file 2. Fifty seven per cent (77/136) 
data points had intervention durations of up to 14 
days, 21% (28/136) had intervention durations 
between 15 days and 30 days, 19% (26/136) had 
intervention durations longer than 30 days but 
within six months, and 4% (5/136) had intervention 
durations longer than six months.
Overall, we saw a mean change of −130 mmol 
(95% confidence interval −145 to −115, P<0.001, 
I2=99.1%) in 24 hour urinary sodium, −4.26 mm 
Hg (−4.89 to −3.62, P<0.001, I2=77.8%) in systolic 
blood pressure, and −2.07 mm Hg (−2.48 to −1.67, 
P<0.001, I2=76.6%) in diastolic blood pressure (fig 2). 
We used different correlation coefficients to calculate 
the variance, which yielded similar pooled estimates 
of difference in systolic blood pressure (ranging from 
−4.59 mm Hg (−5.27 to −3.91) to −4.18 mm Hg (−4.59 
to −3.51)) and diastolic blood pressure (ranging 
from −2.04 mm Hg (−2.46 to −1.63) to −2.13 mm Hg 
(−2.58 to −1.67)). Sodium reduction was associated 
with separately statistically significant reductions 
in blood pressure for most subgroups studied. As 
reflected by the I2 values, the magnitude of effect 
varied substantially between contributing trials, as 
well as between many of the subgroups (fig 3).
Association of magnitude of sodium reduction with 
size of blood pressure reduction
The meta-analysis of trials by group of achieved 
sodium reduction (fig 2) identified no clear 
association between the magnitude of sodium 
reduction and magnitude of either the systolic blood 
pressure reduction (P trend=0.09) or the diastolic 
blood pressure reduction (P trend=0.63). Likewise, 
the univariable meta-regression analyses including 
all studies (table 1) showed no association of blood 
pressure effect with magnitude of sodium reduction. 
However, the magnitude of the change in 24 hour 
urinary sodium excretion was positively associated 
with the change in blood pressure after adjusting for 
intervention duration, mean age, percentage of female 
sex, percentage of white ethnicity, and baseline blood 
Additional records identified through reference lists
Full text articles excluded
Not an intervention study
No randomisation
Intervention was not related to salt
Concomitant intervention not equally applied
Participants not meeting inclusion criteria
Sodium intake not measured by 24-hour urine
Blood pressure was not measured
General or not study outcome papers (eg, protocols)
Animal study
Data could not be extracted for outcomes of interest
Duplicate study
13
21
27
55
13
20
9
11
2
66
92
Records aer duplicates removed
Records identified through database searching
Records excluded
Full text articles assessed for eligibility
Number of studies included in quantitative synthesis (meta-analysis)
329
133
Data points for primary analysis
136
Data points for subgroup analyses
169
462
9628
9166
17 476 1
Fig 1 | Flowchart for inclusion criteria
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pressure in the multivariable meta-regression. In these 
analyses, each 50 mmol reduction in 24 hour urinary 
sodium was associated with a 1.10 mm Hg (0.66 to 
1.54) decrease in systolic blood pressure and a 0.33 
mm Hg (0.04 to 0.63) decrease in diastolic blood 
pressure. Sensitivity analyses excluding studies with 
missing data other than ethnicity (18 studies) did not 
change the results substantially. We did not exclude 
studies missing only ethnicity data because this 
could be estimated with high confidence based on the 
study country. The analysis of studies with more than 
two levels of dietary sodium intake provided further 
support for a dose-response association between 
magnitude of sodium reduction and magnitude of 
systolic blood pressure response (supplementary fig 
1). Findings in the subsidiary analyses for DBP were 
less clear.
Association of duration of sodium reduction 
intervention with size of blood pressure reduction
The meta-analysis of trials by intervention duration 
(fig 4) identified no overall association between the 
duration of the sodium reduction intervention and 
the magnitude of either the systolic blood pressure 
reduction (P trend=0.87) or the diastolic blood pressure 
reduction (P trend=0.11). Likewise, the univariable 
meta-regression analyses of all trials showed no 
association of blood pressure effect with duration of 
sodium reduction and neither did the multivariable 
meta-regressions. The six studies that recorded 
multiple measurements at different time points 
showed no apparent difference in the pattern of blood 
pressure lowering over time (supplementary fig 2), 
which corresponded to the meta-regression analyses. 
In the subsidiary analysis of studies with intervention 
duration >14 days compared with ≤14 days, the effect 
of each 50 mmol reduction in 24 hour urinary sodium 
excretion on systolic blood pressure reduction was 
approximately twice as large in the studies of longer 
intervention duration (2.13 mm Hg; 0.85 to 3.40 v 
1.05 mm Hg; 0.40 to 1.70). The univariable meta-
regression analyses restricted to longer trials and trials 
with smaller reductions in sodium excretion showed 
inverse associations between intervention duration 
and magnitude of systolic blood pressure reduction 
but these were not apparent in the corresponding 
multivariable meta-regression analyses (table 1) with 
I2 reduced to 24.9%. There was no consistent pattern 
of association between intervention duration and 
reduction in diastolic blood pressure.
Association of age, sex, race, baseline sodium 
intake, and baseline blood pressure with the size of 
blood pressure fall with 50 mmol sodium reduction
The analysis of trial subgroups standardised to a 50 
mmol sodium reduction (fig 3) identified positive 
associations between the magnitude of systolic 
blood pressure reduction and baseline age and 
baseline systolic blood pressure (both P trend=0.01), 
and statistically significant heterogeneity by race 
(P=0.005). We observed no association for baseline 
sodium intake (P trend=0.20) or blood pressure 
status (P trend=0.08) and there was no detectable 
heterogeneity by sex (P=0.42). The meta-regression 
analyses (table 1) provided support for independent 
effects of age, ethnicity, and baseline blood pressure 
as modifiers of the effect of sodium reduction on blood 
pressure.
Study quality and publication bias
Most studies did not report whether there was 
random sequence generation (80.1%, 109/136) 
Systolic blood pressure
  Q1
  Q2
  Q3
  Q4
  Q5
  Overall
Diastolic blood pressure
  Q1
  Q2
  Q3
  Q4
  Q5
  Overall
-5.74 (-7.67 to -3.81)
-4.08 (-5.58 to -2.58)
-4.09 (-5.68 to -2.49)
-4.46 (-5.71 to -3.20)
-3.21 (-4.13 to -2.28)
-4.26 (-4.89 to -3.62)
I2=77.8%
-2.64 (-3.87 to -1.42)
-1.59 (-2.46 to -0.71)
-2.09 (-3.18 to -1.01)
-1.87 (-2.49 to -1.24)
-2.09 (-2.78 to -1.40)
-2.07 (-2.48 to -1.67)
I2=76.6%-9 -6 -3 0
Group of
sodium
change
Mean difference
in blood pressure
(mm Hg) (95% CI)
Mean difference
in blood pressure
(mm Hg) (95% CI)
-259 (-336 to -208)
-180 (-207 to -149)
-114 (-149 to -96)
-79 (-94 to -70)
-43 (-67 to 8)
-131 (-336 to 8)
I2=99.1%
-259 (-336 to -208)
-180 (-207 to -149)
-114 (-149 to -96)
-79 (-94 to -70)
-43 (-67 to 8)
-130 (-336 to 8)
Change of
sodium (mmol),
mean (range)
27
27
27
26
28
135
27
27
27
27
28
136
P trend for SBP = 0.09, P trend for DBP = 0.63
SBP = systolic blood pressure, DBP = diastolic blood pressure 
No of
data
points
1106
1130
1267
1536
7134
12 173
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1267
1560
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Total
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Fig 2 | Association of magnitude of sodium reduction (mmol) with size of blood pressure reduction (mm Hg)
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or appropriate allocation concealment (83.8%, 
114/136). Only 41.9% (57/136) studies were 
double blinded and 52.9% (72/136) had inadequate 
blinding (open studies, or with only participants or 
outcome observers blinded). Most studies had low 
rates of loss to follow-up and there was low risk of 
selective outcome reporting (supplementary figure 3, 
supplementary file 3). Although the information for 
assessing individual study quality was limited, the 
overall evidence should be considered of fairly high 
quality since only randomised trials were included 
and only a small proportion of studies had significant 
missing data.
Egger’s regression test suggested asymmetry of 
funnel plots for both systolic blood pressure change 
(P<0.001) and diastolic blood pressure change 
(P=0.005) (supplementary figure 4). Use of the trim 
and fill method did not change the results and the 
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Fig 3 | Effects of age, sex, ethnicity, baseline sodium intake, baseline blood pressure, and blood pressure status on the size of blood pressure 
reduction (mm Hg) achieved with a 50 mmol reduction in sodium excretion
 o
n
 9 M
arch 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m315 on 24 February 2020. Downloaded from 
RESEARCH
the bmj | BMJ 2020;368:m315 | doi: 10.1136/bmj.m315 7
contour enhanced funnel plots did not suggest under-
reporting of studies with less statistical significance 
(supplementary figure 5). Asymmetry of the funnel 
plots is more likely to arise from other differences in 
study characteristics.
Discussion
Principal findings
This meta-analysis shows that sodium reduction leads 
to a significant reduction in systolic blood pressure in 
adults, both female and male, all ethnic groups, and 
in both hypertensive and normotensive populations. 
Diastolic blood pressure also decreased significantly 
in most participant subgroups. There was a dose-
response relation with a greater reduction in sodium 
intake producing a greater fall in blood pressure. 
Populations with older age and higher baseline blood 
pressure achieved greater blood pressure lowering 
from the same amount of sodium reduction and so did 
non-white compared with white populations.
Table 1 | Coefficient statistics of unadjusted and multivariable meta-regression on the association between blood pressure change and 24 hour urinary 
sodium change and other covariates
Dependent variables and studies Independent variables
Unadjusted Multivariable
Coefficient* (95% CI) P value Coefficient* (95% CI) P value
Change in SBP (mm Hg)
All studies (135 data points)
Change of 24 hour urinary sodium (mmol) 0.007 (−0.002 to 0.016) 0.106 0.022 (0.013 to 0.031) <0.001
Duration of intervention (days) −0.003 (−0.006 to 0.001) 0.124 0.000 (−0.003 to 0.003) 0.849
Mean age (years) 0.121 (0.073 to 0.169) <0.001 0.111 (0.046 to 0.177) 0.001
Percentage of female sex 2.258 (−0.794 to 5.309) 0.146 −0.412 (−3.170 to 2.346) 0.768
Percentage of white ethnicity −3.039 (−5.397 to −0.680) 0.012 −2.957 (−5.000 to −0.913) 0.005
Mean baseline SBP (mm Hg) 0.102 (0.065 to 0.138) <0.001 0.074 (0.030 to 0.118) 0.001
Studies with ≤14 days’ intervention  
(77 data points)
Change of 24 hour urinary sodium (mmol) 0.015 (−0.001 to 0.030) 0.064 0.021 (0.008 to 0.034) 0.002
Duration of intervention (days) 0.208 (−0.084 to 0.500) 0.160 0.071 (−0.182 to 0.324) 0.577
Mean age (years) 0.180 (0.106 to 0.254) <0.001 0.105 (−0.006 to 0.217) 0.064
Percentage of female sex 2.701 (−1.438 to 6.841) 0.198 −0.233 (−4.031 to 3.566) 0.903
Percentage of white ethnicity −5.061 (−8.923 to −1.199) 0.011 −2.787 (−6.343 to 0.770) 0.123
Mean baseline SBP (mm Hg) 0.132 (0.080 to 0.185) <0.001 0.076 (0.002 to 0.150) 0.044
Studies with >14 days’ intervention  
(58 data points)
Change of 24 hour urinary sodium (mmol) 0.043 (0.019 to 0.067) 0.001 0.043 (0.017 to 0.068) 0.002
Duration of intervention (days) −0.003 (−0.006 to −0.001) 0.016 0.000 (−0.002 to 0.003) 0.813
Mean age (years) 0.107 (0.013 to 0.201) 0.027 0.107 (0.012 to 0.203) 0.028
Percentage of female sex 0.523 (−4.924 to 5.970) 0.848 −0.421 (−5.337 to 4.496) 0.864
Percentage of white ethnicity −1.251 (−3.973 to 1.471) 0.361 −3.342 (−6.071 to −0.614) 0.017
Mean baseline SBP (mm Hg) 0.067 (0.004 to 0.129) 0.036 0.058 (−0.003 to 0.120) 0.062
Studies with duration >14 days and 
sodium reduction <=100 mmol  
(48 data points)
Change of 24 hour urinary sodium (mmol) 0.059 (0.023 to 0.094) 0.002 0.058 (0.022 to 0.093) 0.002
Duration of intervention (days) −0.003 (−0.005 to −0.001) 0.007 0.001 (−0.001 to 0.003) 0.410
Mean age (years) 0.113 (0.029 to 0.198) 0.010 0.110 (0.032 to 0.188) 0.007
Percentage of female sex 0.945 (−4.278 to 6.169) 0.717 0.155 (−3.854 to 4.164) 0.938
Percentage of white ethnicity −1.302 (−3.943 to 1.340) 0.326 −3.497 (−5.724 to −1.271) 0.003
Mean baseline SBP (mm Hg) 0.083 (0.025 to 0.141) 0.006 0.087 (0.035 to 0.140) 0.002
Change in DBP (mm Hg)
All studies (136 data points)
Change of 24 hour urinary sodium (mmol) 0.000 (−0.006 to 0.006) 0.972 0.007 (0.001 to 0.013) 0.028
Duration of intervention (days) −0.001 (−0.003 to 0.001) 0.555 0.000 (−0.002 to 0.002) 0.980
Mean age (years) 0.068 (0.036 to 0.100) <0.001 0.041 (−0.002 to 0.084) 0.062
Percentage of female sex −0.373 (−2.327 to 1.582) 0.707 −1.480 (−3.343 to 0.383) 0.118
Percentage of white ethnicity −1.102 (−2.569 to 0.366) 0.140 −0.909 (−2.249 to 0.430) 0.182
Mean baseline DBP (mm Hg) 0.102 (0.071 to 0.133) <0.001 0.088 (0.049 to 0.127) <0.001
Studies with ≤14 days’ intervention  
(77 data points)
Change of 24 hour urinary sodium (mmol) 0.003 (−0.007 to 0.014) 0.531 0.007 (−0.002 to 0.015) 0.134
Duration of intervention (days) 0.302 (0.127 to 0.478) 0.001 0.174 (0.006 to 0.343) 0.043
Mean age (years) 0.104 (0.055 to 0.154) <0.001 0.021 (−0.054 to 0.095) 0.586
Percentage of female sex −0.381 (−3.011 to 2.249) 0.774 −1.357 (−3.722 to 1.007) 0.256
Percentage of white ethnicity −1.230 (−3.590 to 1.130) 0.302 −0.570 (−2.701 to 1.561) 0.596
Mean baseline DBP (mm Hg) 0.126 (0.086 to 0.166) <0.001 0.099 (0.036 to 0.162) 0.003
Studies with >14 days’ intervention  
(59 data points)
Change of 24 hour urinary sodium (mmol) 0.015 (0.001 to 0.029) 0.035 0.013 (−0.002 to 0.029) 0.094
Duration of intervention (days) −0.001 (−0.003 to 0.000) 0.157 0.000 (−0.002 to 0.002) 0.983
Mean age (years) 0.022 (−0.039 to 0.083) 0.472 0.035 (−0.033 to 0.103) 0.308
Percentage of female sex −1.213 (−4.464 to 2.039) 0.458 −1.263 (−4.617 to 2.091) 0.453
Percentage of white ethnicity −0.780 (−2.472 to 0.911) 0.359 −1.493 (−3.353 to 0.368) 0.113
Mean baseline DBP (mm Hg) 0.049 (−0.011 to 0.109) 0.110 0.048 (−0.015 to 0.110) 0.134
Studies with duration >14 days and 
sodium reduction ≤100 mmol  
(49 data points)
Change of 24 hour urinary sodium (mmol) 0.018 (−0.002 to 0.037) 0.081 0.013 (−0.010 to 0.035) 0.258
Duration of intervention (days) −0.001 (−0.002 to 0.000) 0.049 0.000 (−0.002 to 0.001) 0.810
Mean age (years) 0.032 (−0.019 to 0.082) 0.210 0.041 (−0.017 to 0.099) 0.162
Percentage of female sex −1.343 (−4.122 to 1.437) 0.336 −0.753 (−3.557 to 2.050) 0.591
Percentage of white ethnicity −0.370 (−1.848 to 1.109) 0.617 −0.979 (−2.544 to 0.586) 0.214
Mean baseline DBP (mm Hg) 0.059 (0.006 to 0.111) 0.029 0.058 (0.003 to 0.113) 0.040
SBP=systolic blood pressure; DBP=diastolic blood pressure.
*The coefficient means the change of the dependent variable (change in SBP or DBP) with each unit increase of the independent variables.
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Overall, the duration of the sodium reduction 
intervention was not associated with the size of the 
change in blood pressure, although short term studies 
of less than 15 days’ duration appear to underestimate 
the effect of sodium reduction on blood pressure. With 
few long term studies available, additional research is 
required to draw a definitive conclusion about whether 
prolonged sodium reduction influences the magnitude 
of the blood pressure lowering.
Strengths and limitations of the study
This meta-analysis represents a substantial update and 
enhancement compared with previous overviews. The 
selective inclusion of studies that used 24 hour urine 
collections to estimate intervention effect on sodium 
intake reduced the risk of bias, while the inclusion 
of studies with concomitant interventions applied in 
the same way to both intervention and control arms 
maximised the available data and the statistical power 
of the analyses. Likewise, the inclusion of studies 
regardless of the length of the duration of intervention 
enabled a robust and powerful examination of the 
effects of intervention duration on outcomes. The 
extensive sensitivity analyses provided for a full 
understanding of the strengths and weakness of the 
findings. There were, however, limitations in regard to 
our capacity to assess the quality of the studies. There 
was substantial heterogeneity across the included 
studies, but this was largely explained by some the of 
study characteristics in the meta-regression analyses. 
When the analyses were limited to studies with 
duration of more than 14 days and a sodium reduction 
of up to 100 mmol, the I2 statistics for heterogeneity 
reduced to 24.9%. The use of study level data rather 
than individual participant data greatly reduced 
the power of the analyses, although this limitation 
was somewhat offset by the large number of studies 
available. Different studies defined hypertension using 
different criteria and there was limited capacity to 
quantify the effects of pharmaceutical treatments on 
baseline diagnoses of hypertension or baseline blood 
pressure measurements. Finally, our use of random 
effects meta-analysis has resulted in wider confidence 
intervals but might better reflect uncertainty about the 
true constancy of effects across included trials.
Comparison with other studies
Effect of sodium reduction on blood pressure and 
the dose-response relation
The overall effect of sodium reduction on blood pressure 
has been observed in several previous meta-analyses, 
despite different trial selection criteria.12  21  160  161 We 
also observed strong associations of the magnitude 
of sodium reduction with the magnitude of the fall 
in systolic blood pressure,11 21 and interactions of 
age, race, and baseline blood pressure with size of 
the systolic blood pressure fall, as shown in previous 
reviews.162 163 However, the 2.2 mm Hg reduction in 
systolic blood pressure for each 100 mmol reduction 
in 24 hour urinary sodium observed in the current 
overview is substantially less compared with the 3.83 
mm Hg reduction reported in a previous overview.164 
The difference may be owing to the inclusion of studies 
with sodium intake estimated from fractional urine 
collections in the previous review.164 Another overview 
that included only studies with at least four weeks’ 
intervention and only moderate 24 hour urinary 
sodium reduction identified a 5.8 mm Hg reduction in 
SBP for each 100 mmol reduction in sodium,21 which 
is similar to the effect found in our subgroup analysis 
of studies longer than 14 days with a sodium reduction 
≤100 mmol, further highlighting the sensitivity of the 
estimated strength of the dose-response association to 
the type of studies included in the analysis.
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Fig 4 | Association of duration of sodium reduction intervention with size of blood pressure reduction (mm Hg)
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Previous overviews have generated uncertainty 
regarding the effects of sodium reduction among 
individuals with different levels of starting blood 
pressure. Some reports have suggested much larger 
effects in hypertensive individuals compared with non-
hypertensive individuals,21 while others suggested 
that sodium reduction is of value only in those with 
hypertension.11 12 The conclusion that there is no value 
in non-hypertensive individuals is dependent upon the 
results from very short term studies in which sodium 
reduction had a limited effect on blood pressure and 
in which there were adverse effects on other markers 
of cardiovascular risk. The responses of the renin-
angiotensin system and sympathetic nervous system 
as well as adverse metabolic effects associated with 
acute large falls in dietary sodium do not, however, 
appear to be present in longer term interventions21 
165 and it is unlikely that short term unfavourable 
metabolic effects would override the long term benefits 
anticipated from sustained blood pressure lowering 
of moderate magnitude. Our review identifies an 
approximate doubling of the effect of sodium reduction 
on blood pressure in studies of longer than two weeks’ 
duration versus shorter studies, indicating that the 
full effects of dietary sodium reduction require several 
weeks to become apparent. Very short term studies of 
sodium reduction are not a sound basis for drawing 
conclusions about the effects of sodium reduction 
on blood pressure and are not helpful in formulating 
policy recommendations for public health.
Analyses that simply separate studies based upon 
those that included hypertensive, non-hypertensive, 
or mixed populations are weak because the definition 
of hypertension is arbitrary and there is a rationale 
for expecting a graded interaction between sodium 
reduction, blood pressure reduction, and starting blood 
pressure. In the present analysis, meta-regressions 
based on mean starting blood pressure levels of 
participants in each study provided for a much more 
nuanced evaluation of the effects of starting blood 
pressure on the size of the blood pressure fall achieved 
with sodium reduction. These analyses showed that 
sodium reduction produced a progressively greater 
reduction in blood pressure among those with higher 
starting blood pressure levels, but also that sodium 
reduction substantially lowered blood pressure, even 
among those with starting systolic blood pressure 
levels as low as 120 mm Hg. These findings indicate 
potentially important health benefits from sodium 
reduction among normotensive as well as hypertensive 
individuals. More importantly, sodium reduction 
among normotensive individuals could potentially 
avert or delay the development of hypertension with 
ageing as the association between sodium intake and 
blood pressure is greater at older age.3
The differential blood pressure lowering effect 
of sodium reduction across different ethnic groups 
has been observed in various studies and meta-
analyses12  21  166; specifically, there was a greater 
blood pressure reduction in non-white populations 
compared with white populations for the same 
amount of sodium reduction. Some authors explained 
this phenomenon as caused by differential “salt 
sensitivity.”167 Others have shown that the difference 
in the responsiveness of the renin-angiotensin system 
to sodium reduction among various ethnic groups is 
at least partially responsible.166 Nonetheless, while 
population wide sodium reduction is recommended, 
the cost effectiveness for some particular populations 
is potentially greater. This has important public health 
implications, especially in regions where resources are 
constrained.
The findings from this overview of randomised trials 
conflict directly with findings from the Prospective 
Urban Rural Epidemiology (PURE)168 study, which 
reported that associations between sodium intake 
and systolic blood pressure are observed only among 
communities with very high sodium intake (>5.08 g or 
221 mmol sodium/day, equivalent to 13 g/day salt). 
We observed very clear effects of sodium reduction on 
both systolic and diastolic blood pressure at levels of 
sodium intake far below this. Measurement errors and 
uncontrolled confounding in the PURE study have 
likely biased conclusions about the association of 
sodium intake and blood pressure.16 169
Impact of intervention duration of sodium reduction
The optimal method to assess the impact of duration 
of sodium reduction on the magnitude of blood 
pressure reduction would be to collate data from 
studies that measure change of sodium and change 
of blood pressure at multiple time points. In practice, 
however, most studies made measurements only once 
at completion of follow-up. Neither the univariable 
nor the multivariable meta-regressions identified an 
effect of intervention duration on the size of the blood 
pressure fall achieved with sodium reduction. The 
power of the analyses was strengthened by the wide 
range of intervention durations recorded (from three 
days to five years) but limited by the highly skewed 
distribution of the studies, with most being of short or 
very short duration. Among the 133 studies included, 
77 were shorter than 15 days’ duration and only five 
extended beyond six months. The DASH sodium trial 
that assessed effects at four time points over one 
month showed with some rigour that blood pressure 
effects from sodium reduction were clearly greater at 
week 4 compared with earlier weeks.170
Conclusions and policy implications
Sodium reduction resulted in lower blood pressure 
among a very broad group of populations with a strong 
dose-response relation between the magnitude of the 
sodium reduction achieved and the magnitude of the 
fall in blood pressure. The effects of sodium reduction 
were more evident at higher starting blood pressure 
levels, older ages, and among non-white populations, 
but almost every population group examined achieved 
a reduction in blood pressure. In trials of more than two 
weeks’ duration, the dose-response relation between 
sodium reduction and blood pressure fall was greater 
than that in trials of shorter duration, but there was 
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limited evidence that interventions of longer duration 
further increased the effects of sodium reduction 
on blood pressure. Longer term trials that achieve 
sustained sodium reduction and make multiple 
assessments of blood pressure are required to properly 
assess this issue.
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